Efficacy of deoxycholate amphotericin B and unilamellar liposomal amphotericin B in prophylaxis of experimental Aspergillus fumigatus endocarditis

Mayo Clin Proc. 1997 Nov;72(11):1022-7. doi: 10.4065/72.11.1022.

Abstract

Objective: To evaluate and compare in vivo the protective efficacy of unilamellar liposomal amphotericin B (L-AmB) with that of deoxycholate amphotericin B (D-AmB) in experimental endocarditis.

Material and methods: In the rabbit model of experimental Aspergillus fumigatus endocarditis, two doses of each antifungal agent (1.5 mg/kg each) were administered intravenously at 4 hours and at 30 minutes before challenge with an inoculum of A. fumigatus. Three days later, the animals were sacrificed, and the aortic vegetations were analyzed.

Results: All 19 animals that did not receive chemoprophylaxis acquired endocarditis. In contrast, endocarditis developed in 2 of 10 animals pretreated with D-AmB (P < 0.01) and 3 of 8 animals pretreated with L-AmB (P < 0.01). Both D-AmB and L-AmB prevented the development of endocarditis due to A. fumigatus and decreased the concentration of fungi in the aortic vegetations by more than 1 log10.

Conclusion: In the rabbit experimental model of Aspergillus endocarditis, D-AmB and L-AmB were equally effective in reducing the incidence of the infection and the tissue burden of fungi.

MeSH terms

  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use*
  • Animals
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / therapeutic use*
  • Aspergillosis / microbiology*
  • Aspergillosis / prevention & control*
  • Aspergillus fumigatus / drug effects*
  • Cholagogues and Choleretics
  • Deoxycholic Acid
  • Disease Models, Animal
  • Endocarditis / microbiology*
  • Endocarditis / prevention & control*
  • In Vitro Techniques
  • Liposomes
  • Male
  • Rabbits

Substances

  • Antifungal Agents
  • Cholagogues and Choleretics
  • Liposomes
  • Deoxycholic Acid
  • Amphotericin B